Regeneron reported promising early clinical data demonstrating a 100% response rate for Lynozyfic, its T cell engager therapy, in a study of small smoldering multiple myeloma patients. This precancerous condition can progress to active disease, and Regeneron is aiming to expand Lynozyfic’s indications beyond current cancer types. These results mark a significant milestone in T cell engager therapy development, potentially broadening immunotherapy impact on hematologic malignancies.